Explore our insights

We are pleased to present the Monthly Dealtracker that captures the recent deal activities in India.

The Indian tax and regulatory space is changing at an unprecedented rate. We are witnessing policy announcements, legislative changes, judicial precedents and clarifications almost daily. This has made it challenging for corporate professionals to stay abreast of relevant developments. The aim of the TaxPod series is to keep you updated with key tax and regulatory developments of the past month, in under 5 minutes.

This edition covers updates for the months of November 2019 (Volume 1) and December 2019 (Volume 2). We hope you find these bulletin informative and useful.

Tax Conundrum of Excess Consideration Received by Retiring Partner

The Indian tax and regulatory space is changing at an unprecedented rate. We are witnessing policy announcements, legislative changes, judicial precedents and clarifications almost daily. This has made it challenging for corporate professionals to stay abreast of relevant developments. The aim of the TaxPod series is to keep you updated with key tax and regulatory developments of the past month, in under 5 minutes.

Finding best company for Union budget 2021-2022 analysis report? You just need to join us, as our panel of experts decode Budget 2021-22 and help you understand its impact.

Get detailed analysis of Budget 2022 here

India has the potential to be one of the pharma superpowers of the future. The industry has evolved over the years from selling generic drugs in India, investing in research and development of niche drugs and selling in highly regulated international markets. Despite a challenging environment amidst talks of slowdown, pricing pressure and regulatory actions, the industry maintained a reasonable growth.